H.R. 9000 · 119th Congress · Health
SCREEN for Type 1 Diabetes Act of 2026
- IntroducedMay 21, 2026 Done
- CommitteeReferred to Energy and Commerce Current stage
- House floorNot yet Not reached yet
- Senate floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
What it does
The Congressional Research Service hasn’t published a summary of this bill. Read the full text on Congress.gov.Who lobbies on it
1 organization · 1 filing, incl. 1 naming only S. 4612 · Q2 2026–Q3 2026One square per quarter since introduction, oldest left. Filled = named H.R. 9000 or S. 4612 that quarter.
-
Revvity, Inc.
1 of 2 quarters
“Diagnostic test reimbursement and policies Proposals related to newborn screening HR 4709 - Newborn Screening Saves Lives Act Reauthorization Act of 2025 H.R. 2810, Family Cord Blood Banking Act S. 4612 SCREEN for Type 1 Diabetes Act Newborn Screening Amendment to NDAA”
$115K lobbying spend in 2026 to date, all issuesQ2 2026 filing · names S. 4612 only
Organizations that named H.R. 9000 or its companion S. 4612 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Reports naming only S. 4612 are included and tagged. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Members sponsoring the companion, S. 4612, are counted on that bill’s page, not here. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.
Actions
2 actions · newest first- May 21, 2026Referred to the House Committee on Energy and Commerce.
- May 21, 2026Introduced in House